Pitch Sessions: Global Leaders in Brain & Mental Health Innovation

​Mental Health Day, presented by THE REAL Mental Health Foundation & Convergence Partners.

Founders will take us on a journey on how their technology and solutions have changed the game in their respective sectors. With a focus on neurodegenerative diseases and digital therapeutics, these founders provide unique and critical insight to a rapidly growing global unmet prevention , management, and treatment need. Join industry leaders, experts, and investors as we discuss these scalable, evidence-based solutions and the next steps in bringing these solutions to the patient population offering hope and improved quality of life.

Explore all panels: thereal.care/davos

Speakers:
- Guillaume Blivet, Co-founder & CIO, REGEnLIFE
- Dr. Chris Rehese, Founder & CEO, neotiv
- Laura Johnson, Co-Founder & CEO, BrainScape
- Matthias Gutknecht, Co-Founder & Managing Partner, SwissDTx

REGEnLIFE:

REGEnLIFE is a French medtech and neurotech company at the forefront of neuroscience innovation, using phototherapy for non-invasive brain-gut stimulation. This novel method shows potential in treating neuroinflammation-related diseases such as Alzheimer's, depression, concussion, and multiple sclerosis. Their cutting-edge device, targeting both brain and gut, aims to enter the neurological disease and mental health market by 2026. Preclinical studies demonstrated safety and efficacy in Alzheimer's, multiple sclerosis, and depression models. First-in-human trials showed promising results in Alzheimer's and sport-related concussion. A pivotal clinical trial for Alzheimer's disease is ongoing, while preparations are underway for market launch in concussion treatment. The therapy is delivered through a helmet and abdominal belt, classified as a Class IIa medical device. This non-invasive, cost-effective solution can be both  administered in hospital or at home. REGEnLIFE holds a robust patent portfolio across various nations, ensuring comprehensive intellectual property control. Financially, the company has secured over €8M in pre-series A funding since its incorporation in 2016 and is now seeking €10M in series A funding to further their advancements. This investment will drive them towards achieving their development goals and potentially revolutionizing brain and mental health.

neotiv
Neotiv is a company that focuses on developing digital cognitive health solutions. They specialize in creating software tools and applications designed to assess and monitor cognitive functions, primarily aimed at early detection and intervention in cognitive decline and related neurological conditions such as Alzheimer's disease. By leveraging digital technology, Neotiv aims to provide accessible and efficient tools for both individuals and healthcare professionals to track cognitive health over time. Convergence Partners, known for investing in innovative and impactful tech companies, includes Neotiv in its portfolio, supporting the company's mission to advance cognitive health diagnostics.

SwissDTX
Swissdtx is a startup company that focuses on developing innovative solutions in the field of digital therapeutics. Led by CEO Matthias Gutknecht, Swissdtx aims to harness the power of digital technologies to create therapeutic tools that improve patient outcomes and enhance healthcare delivery. Digital therapeutics often involve software-driven interventions that can be used independently or in conjunction with traditional medical treatments. By focusing on this cutting-edge area, Swissdtx is part of a growing industry that seeks to revolutionize how healthcare is delivered and experienced.

Brainscape
BrainScape Medical is a Swiss neurotech company with a leading innovation in below the skin EEG technology (Epios®) for minimally-invasive, long-term, brain monitoring and stimulation. The tiny electrode technology is going to positively disrupt the way we treat chronic brain disorders and bring much needed help to millions of people in a way previously not possible. We are starting by addressing the need for high quality, practical brain monitoring as we see this as the keystone of success in diagnosis, neural modulation and treatment. With the introduction of neural stimulation protocols we will be able to offer patients a seamlessly integrated monitoring and therapy solution for personalised, at home brain management. Our solutions will reduce significant barriers to care, waiting times, stigma, ineffective medication and get people back on track sooner.